Displaying drugs 1726 - 1750 of 1783 in total
Gantenerumab
Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs). As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and aggregation to form NFTs and cause neurodegeneration, large...
Investigational
Matched Description: … dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta …
Aranidipine
Aranidipine is a novel dihydropyridine derivative that gives rise to two active metabolites (M-1α and M-1β) that exhibit hypotensive activity. It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.
Experimental
Methoserpidine
Experimental
Oxidized coenzyme A
Experimental
Z-Val-Ala-Asp fluoromethyl ketone
Non-methylated, competitive, and irreversible inhibitor of caspase 1, as well as other caspases,1 which can be used directly with purified enzymes. It does not require an esterase to hydrolyze the O-methyl ester like the cell-permeable form, Z-Val-Ala-Asp(O-Me) fluoromethyl ketone.
Experimental
Hexanoyl-CoA
Experimental
Octanoyl-Coenzyme A
Experimental
2-carboxypropyl-coenzyme A
Experimental
CoA-S-acetyl 5-bromotryptamine
Experimental
4-hydroxybenzyl coenzyme A
Experimental
3-Dehydroshikimate
Experimental
Methacrylyl-Coenzyme A
Experimental
CoA-s-acetyl tryptamine
Experimental
3-Hydroxybutyryl-Coenzyme A
Experimental
GDP-alpha-D-mannuronic acid
Experimental
Bietaserpine
Experimental
Niguldipine
Niguldipine is a calcium channel blocker drug (CCB) with a1-adrenergic antagonist properties.
Experimental
CoA-S-trimethylene-acetyl-tryptamine
Experimental
Trifluoroacetonyl coenzyme A
Experimental
Displaying drugs 1726 - 1750 of 1783 in total